|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0010656,
umls-concept:C0027651,
umls-concept:C0031809,
umls-concept:C0080103,
umls-concept:C0086418,
umls-concept:C0162638,
umls-concept:C0205177,
umls-concept:C0376315,
umls-concept:C1521747,
umls-concept:C1521970
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2001-11-26
|
|
pubmed:abstractText |
Apoptosis is of important significance in the pathogenesis of cancer. Many methods are available for the measurement of apoptosis but the 'gold standard' is to identify apoptotic cells by their morphological features using microscopy. Caspase 3 is a cytosolic enzyme that is activated only in cells committed to undergo apoptosis. The activation of caspase 3 precedes the development of the classical morphological features of apoptosis. Using immunohistochemistry with an antibody against the active form of caspase 3, the apoptotic index (AI) was measured in 116 samples of human breast tissue (22 normal/benign and 94 invasive carcinomas). The AI obtained by measuring caspase activation has a strong correlation with the AI derived by morphological assessment (r = 0.736, P < 0.01). The AI is higher in the invasive group than in the benign group (P = 0.008), and in invasive cancer high AI is associated with high tumour grade (P = 0.013), positive node status (P < 0.001) and negative steroid receptor status (P = 0.001 for ER; P = 0.004 for PR). No significant association is observed between AI and tumour size. Measurement of apoptosis by immunohistochemistry using an antibody against the active form of caspase 3 is therefore reliable and correlates strongly with morphological assessment.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10037180,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10209153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10398099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10426397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10732778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10732780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-10769034,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-11048727,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-11048728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-11048729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-12085220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-1400587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-312256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-3791,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-7014501,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-7737654,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-7857705,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-7878464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-8956787,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9307843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9447384,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9513685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9529021,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9577369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9677455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9753316,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9815706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11720439-9988219
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1522-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11720439-Antibodies,
pubmed-meshheading:11720439-Apoptosis,
pubmed-meshheading:11720439-Breast,
pubmed-meshheading:11720439-Breast Diseases,
pubmed-meshheading:11720439-Breast Neoplasms,
pubmed-meshheading:11720439-Carcinoma,
pubmed-meshheading:11720439-Caspase 3,
pubmed-meshheading:11720439-Caspases,
pubmed-meshheading:11720439-Enzyme Activation,
pubmed-meshheading:11720439-Female,
pubmed-meshheading:11720439-Humans,
pubmed-meshheading:11720439-Immunohistochemistry,
pubmed-meshheading:11720439-Lymphatic Metastasis,
pubmed-meshheading:11720439-Neoplasm Invasiveness
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics.
|
|
pubmed:affiliation |
Department of Surgery, University of Manchester, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
